Program
dipropizine
Also written as “R1_PBK_M2301 (levodropropizine)”, “Levopront® syrup 30 mg/5 ml” and “Levotuss”.
Its studies are mostly in Cough · Bronchitis, Chronic, led by 5 companies.
Drug pageDipropizine: every studyMany companies study it; this page follows only the 5 they lead. All 6 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Aug 6, 2010 | Aug 6, 2010 | none ahead |
| Dompé Farmaceutici S.p.Aits history only | 10 open or running | phase 3since Jan 28, 2019 | Jan 28, 2019 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Apr 5, 2012 | Apr 5, 2012 | none ahead |
| Hyundai Pharmits history only | 10 open or running | phase 3since Mar 30, 2018 | Mar 30, 2018 | none ahead |
| Pharmbio Korea | 11 open or running | phase 1since Aug 20, 2025 | Aug 20, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pharmbio Korea only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 20, 2025First study: phase 1 study in Healthy VolunteersFirst studyNCT07161180 · 32 planned · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Pharmbio Korea leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07161180Healthy Volunteers · South Korea | 1 | Recruiting | Oct 30, 2025 | 32 |
How it is read
Names in the registry
- “R1_PBK_M2301 (levodropropizine)”, 1 entry
- “Levopront® syrup 30 mg/5 ml”, 1 entry
- “Levotuss”, 1 entry
- “diphenhydramine + dropropizine + pseudoephedrine”, 1 entry
- “Ambroxol and Levodropropizine”, 1 entry
Conditions, from the studies’ own filings
- Cough, 2 studies
- Bronchitis, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.